Medical marijuana advocates have been pushing the government to lift its ban on cannabis and to allow for medical marijuana sales.
But some medical marijuana advocates are worried the government could use the drug to skirt the ban on marijuana and sell it to patients.
The federal government has long held that cannabis can be used for medicinal purposes and that it’s illegal to sell it for profit.
But a study published last year in the British Medical Journal suggested that a medical marijuana product could be made with the same ingredients as cannabis oil, which can be mixed with other ingredients.
The study, titled “Is Cannabis Oil for Medicinal Purposes?
An Overview,” looked at more than 2,000 patients with chronic pain who were treated with cannabis-based therapies, and concluded that cannabis oil may be used to treat “several different types of chronic pain.”
It said that patients who take cannabis oil often experience better results than those who don’t.
But while the study found that the benefits of cannabis oil were more pronounced in people who received it, it didn’t recommend that it be used as a treatment for chronic pain.
Some critics say the results suggest that cannabis-derived products are better for the average person, not just those who are already prescribed painkillers.
“They’re taking it for pain and not thinking about the fact that it might be used in a medicinal way for a condition where there’s a need for the medication,” said Chris McLean, a physician and member of the Canadian Medical Association.
“There’s no evidence to show that it is a useful treatment for the patient.”
In a statement, Health Canada said the results of the study are still being reviewed.
The agency said it will not change the policy of medical marijuana until it is “validated.”
McLean said the government should wait for the results before making any decisions.
“It’s a good thing that we’re not going to have to wait for it to be approved,” he said.
McLean noted that the government has yet to release the results from the study and added that he is concerned that the results are not being widely reported because the government would prefer the results to be public.
“I’m really concerned about that,” he added.
“Why not get this right and share it and get some real science behind it and see if this helps?”
The report also found that patients were more likely to report pain relief when taking cannabis-infused products than those taking non-infusion products.
But the authors of the report warned that there is no evidence that cannabis products have improved outcomes for people with chronic diseases, such as arthritis or epilepsy.
The authors of that report, from McMaster University, said that there was a “significant correlation” between the use of cannabis and the improvement of symptoms in chronic pain, but the results weren’t conclusive.
“The finding that cannabis improves the pain-relief profile is not surprising given that cannabinoids have been shown to alleviate symptoms of multiple chronic conditions,” the authors wrote.
“However, the finding that there are also effects of cannabinoids on pain and inflammation that are less clear is concerning given that there have been few studies to assess this relationship.”
The authors said that more research is needed to determine the effectiveness of cannabis in treating chronic pain and that further studies should be conducted.
Health Canada says that the country is working on guidelines for the sale of cannabis products to help patients.
And it has launched a website that helps patients find products that they may need, including products from producers and dispensaries.
But in a statement released last month, Health Minister Jane Philpott said that while the government will continue to monitor the health effects of cannabis, it won’t make any changes to the current law to allow it to continue to be sold.
“In order to ensure Canadians have access to the highest quality cannabis, HealthCanada is working with the provinces and territories to set guidelines for product distribution and to ensure they meet the requirements of the current legislation,” the statement read.
“While the new guidelines are being developed, Health will not be changing the current laws governing the sale and distribution of cannabis.”
Health Canada spokesperson Lauren Jansen said the agency is working closely with the Canadian Cancer Society, which is reviewing the results.
The organization’s CEO, Jennifer Lefebvre, said she thinks the results were good but added that there needs to be more research.
“This study provides a lot of information and a lot more work is needed before we can come to a consensus on the effectiveness and the safety of the cannabis oils and other forms of cannabis,” she said.
“But I think it’s important that we don’t rush into any decisions because there’s going to be a lot that’s unknown.”
The federal Conservatives, who hold a majority in Parliament, have also been quick to push back on the report.
“These are not scientific studies,” Health Minister Rona Ambrose said last month.
“You can’t get to the bottom of what these people are experiencing and then say, ‘OK, this is what’s going on